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Highlights: 48 
• Patterns of semicircular canal loss may indicate different etiologies in bilateral 49 
vestibulopathy 50 
• Anterior canals were relatively preserved for aminoglycoside vestibulotoxicity and 51 
Menière’s disease 52 
• Video-head-impulse testing of all six canals may help identify bilateral vestibular loss 53 
etiologies  54 
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ABSTRACT 55 
Objective: Bilateral vestibular loss (BVL) is often diagnosed with great delay and an 56 
underlying cause is only identified in 50-80%. We measured horizontal and vertical 57 
semicircular canal function using the video-head-impulse test (vHIT) and hypothesized that 58 
specific vHIT-patterns may be linked to certain etiologies.  59 
Methods: We retrospectively analyzed 109 BVL-patients linked to aminoglycoside 60 
vestibulotoxicity (n=16), Menière’s disease (n=10), infectious inner-ear disorders (n=11), 61 
sensorineural hearing-loss (n=11), cerebellar-ataxia-neuropathy-vestibular-areflexia-62 
syndrome (CANVAS, n=5), other causes (n=19) as well as those with unknown origin 63 
(n=47). Vestibulo-ocular reflex gains and cumulative saccade amplitudes were measured with 64 
vHIT, and the functional integrity of all semicircular canals was rated.  65 
Results: Overall, anterior canal hypofunction (n=86/218) was identified significantly 66 
(p<0.001) less often than horizontal (n=186/218) and posterior (n=194/218) hypofunction. 67 
Preserved anterior canal function was associated with aminoglycoside vestibulotoxicity, 68 
Menière’s disease and BVL of unknown origin, while no such sparing was found for inner-ear 69 
infections, CANVAS and sensorineural hearing loss.  70 
Conclusions: Semicircular canal function in BVL shows disease-specific dissociations, 71 
potentially related to reduced vulnerability or superior recovery of the anterior canals.  72 
Significance: In patients with suspected BVL we recommend quantifying vHIT gains and 73 
saccade amplitudes for all semicircular canals as the pattern of canal hypofunction may help 74 
identifying the underlying disorder. 75 
 76 
Keywords: 77 
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1. INTRODUCTION 81 
Bilateral impairment of peripheral-vestibular function is characterized by gait and 82 
postural imbalance and oscillopsia (illusionary movement of the visual surroundings during 83 
head movements) (Dandy, 1941, 1952, Hain et al. , 2013). Gait imbalance is present in up to 84 
99% of patients (Zingler et al. , 2007), while rates of oscillopsia are more variable (range: 85 
44% (Zingler et al. , 2007) - 97% (Black et al. , 2004)). The prevalence for severe bilateral 86 
vestibular loss (BVL) was estimated at 28/100’000 in US-adults (Ward et al. , 2013). In 87 
typical dizziness clinics, BVL is present in 2-4% of all outpatients (Zingler et al. , 2007, Hain 88 
et al. , 2013), which makes it a rather infrequent vestibular disorder. Quality of life, however, 89 
is considerably affected by BVL (Guinand et al. , 2012, Sun et al. , 2014), with >80% of 90 
patients reporting impairment (Zingler et al. , 2008). Likewise, BVL imposes substantial 91 
economic burdens on individuals and the society (Sun et al. , 2014). The course of disease is 92 
chronic in up to 80% (Zingler et al. , 2008), albeit recovery from vestibulotoxicity may occur 93 
(Black et al. , 2001). 94 
These complaints are a consequence of a deficient angular vestibulo-ocular reflex 95 
(aVOR) that normally compensates for head perturbations. At the bedside, the head-impulse 96 
test (HIT) allows a clinical assessment of the aVOR (Halmagyi et al. , 1988). Investigations 97 
for the presence of BVL are often delayed by months to years due to unspecific complaints 98 
and lack of recognition by the clinician (Ahmed et al. , 2012, van de Berg et al. , 2015). A 99 
specific cause of BVL is found only in 50-80% of patients (Rinne et al. , 1998, Zingler et al. , 100 
2007, Kim et al. , 2011, Lucieer et al. , 2016). Vestibulotoxic drugs such as aminoglycoside 101 
antibiotics (10-20%), bilateral Menière’s disease (7-15%) and head trauma with bilateral 102 
inner-ear damage (<10%) are amongst the most frequently identified disorders linked to BVL 103 
(Vibert et al. , 1995, Rinne et al. , 1998, Zingler et al. , 2007, Kim et al. , 2011). 104 
Traditionally, semicircular canal (SCC) function was quantified by use of caloric 105 
irrigation and rotatory-chair testing (Rinne et al. , 1998, Ishiyama et al. , 2006, Kim et al. , 106 
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2011). These approaches, however, have significant limitations, as they only provide 107 
information about the functional state of the horizontal SCCs. Only with the recent 108 
introduction of video-based quantitative head-impulse testing (vHIT) devices, a detailed 109 
assessment of all six horizontal and vertical (anterior, posterior) SCCs became readily 110 
available (MacDougall et al. , 2009, Weber et al. , 2009b, MacDougall et al. , 2013a, b). 111 
With different underlying disorders leading to BVL, we hypothesized that the 112 
individual pattern of SCC hypofunction may be variable. For example, in temporal-bone 113 
specimens of patients with Menière’s disease (MD), varying rates of involvement of the 114 
individual SCCs and the macular organs have been reported (Okuno et al. , 1987). Potentially, 115 
characteristic patterns of SCC hypofunction will facilitate identifying the underlying cause of 116 
BVL and result in earlier and more targeted treatment, eventually improving long-term 117 
outcome. We retrospectively analyzed vHIT measurements in all patients with diagnosed 118 
BVL since the introduction of the vertical vHIT at our dizziness clinic and explored patterns 119 
of vestibular hypofunction with underlying diagnoses.  120 
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2. MATERIAL AND METHODS 121 
 122 
The protocol was approved by the Cantonal ethics commission Zurich (KEK-ZH-123 
2013-0468) and was in accordance with ethical standards laid down in the 2013 Declaration 124 
of Helsinki for research involving human subjects. Since this study was a retrospective 125 
database analysis, written informed consent could not be obtained from the participants. This 126 
approach was in accordance with the approval from the ethics committee. Prior to analysis 127 
patient records/information was anonymized and de-identified.  128 
 129 
2.1 vHIT-recording procedure 130 
The standard vHIT procedure at the University Hospital Zurich (UHZ) requires 20 131 
valid head impulses for each canal (MacDougall et al. , 2013a), with canals tested in pairs 132 
according to the planes of stimulation (horizontal plane, right-anterior-left-posterior (RALP) 133 
plane, left-anterior-right-posterior (LARP) plane). For video-oculography, commercially 134 
available video-head-impulse testing goggles (GN Otometrics, Taastrup, Denmark) with an 135 
infrared camera recording the right eye were used. Horizontal and vertical eye position was 136 
measured with a 250Hz frame rate and head velocity was determined by three orthogonal 137 
gyroscopes. For further analysis, eye and head velocity values were calculated.  138 
 139 
2.2 Patient identification and statistical analysis 140 
All patients evaluated by vHIT had sought medical attention because of gait ataxia or 141 
vertigo/dizziness. The clinical database operated at the UHZ stored all vHITs performed and 142 
was searched for patients with hypofunction in at least one SCC on each side (period: October 143 
1st 2012 to December 15th 2014), finding 110 patients out of 2430 recordings from 2123 144 
patients. We re-analyzed aVOR-gains using OtosuiteV 2.0 (GN Otometrics). The gain of the 145 
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aVOR was calculated as the ratio of cumulative slow-phase eye velocity over cumulative 146 
head velocity from the onset of the head impulse to the moment when head velocity crossed 147 
zero again (Macdougall et al. , 2013b). For the quantification of corrective saccades we used 148 
custom-written MATLAB (The MathWorks, Natick, MA, USA) routines, providing 149 
cumulative overt saccade amplitudes (Weber et al. , 2008, 2009a). Saccades were defined as 150 
‘overt’, if their onset occurred after head velocity crossed zero after the head impulse. 151 
Cumulative saccade amplitude per trial was calculated by adding all overt saccades with peak 152 
velocity >20°/s. Vestibular hypofunction was defined as a reduction in aVOR-gain and/or the 153 
occurrence of overt compensatory saccades with peak velocities >20°/s. For gains, cut-off 154 
values of 0.8 (horizontal canals) and 0.7 (vertical canals) have been proposed by the 155 
manufacturer of the video-goggles to distinguish normal from reduced aVOR-function and 156 
are in line with age-dependent normative values (McGarvie et al. , 2015). 157 
Two experienced neuro-otologists (AAT, KPW) independently reviewed the vHIT-158 
traces and rated individual SCC-function as normal or pathological (Cohen’s kappa=0.86) 159 
(Cohen, 1960) based on 1) reduced aVOR-gain, 2) the presence of corrective saccades, or 3) a 160 
combination of both. In addition, a second rating was obtained taking the presence/absence of 161 
correction saccades into account only. BVL was confirmed in 109 cases, one patient was 162 
excluded because of unilateral vestibular hypofunction. Disagreements were settled by 163 
discussion amongst the reviewers. The underlying cause of BVL was retrieved from the 164 
patients’ files. We followed the AAO-HNS 1995 guidelines for diagnosing MD (1995). 165 
Details on previous CNS-infections, drug treatment and delay for vestibular symptoms were 166 
collected (Appendix A). A diagnosis of bilateral sensorineural hearing loss (SNHL) required 167 
documented hearing impairment as assessed by pure tone audiogram based on CPT-AMA 168 
guidelines (Council on Physical Therapy, 1942) with a CPT value >20% on both sides and 169 
exclusion for other causes. Diagnostic criteria for CANVAS (cerebellar ataxia, neuropathy, 170 
vestibular areflexia syndrome) were based on the definition provided by Szmulewicz 171 
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(Szmulewicz et al. , 2011). The individual patterns of vestibular (hypo)function and the 172 
reported cause of BVL were correlated and an analysis of the occurrence of specific patterns 173 
was made. In those cases with both warm-/cold-water caloric irrigation and vHIT available 174 
(n=66), these two approaches were compared. Unilateral hypofunction was defined as a canal 175 
paresis factor of >25% with a preserved response on the healthy side (Halmagyi et al. , 1997), 176 
while for bilateral hypofunction on caloric irrigation a nystagmus with a mean peak slow-177 
phase velocity of less than 5°/sec on both sides was required (Zingler et al. , 2007). 178 
MATLAB was used for statistical analysis. Fisher’s exact test (Bonferroni-corrected) 179 
was applied to determine significant differences in the frequency of specific conditions. 180 
Median values (±1 median absolute deviation, MAD) were determined for gains and saccade 181 
amplitudes and statistics were based on non-parametric analysis of variance (Kruskal-Wallis 182 
ANOVA, Tukey-Kramer corrected). The level of significance for all statistical tests was 183 
p=0.05. Gain asymmetry was determined using the absolute gain difference between both 184 
sides as this approach avoids exaggerated asymmetry in patients with very small aVOR-gains 185 
(Weber et al. , 2009a). 186 
Currently no established cut-off values are available to identify pathological correcting 187 
saccades after a head-impulse. We therefore obtained a ROC (Receiver Operating 188 
Characteristic) curve to estimate the optimal cut-off value for cumulative saccade amplitudes 189 
based on the reviewers’ ratings and the saccade amplitudes using the built-in MATLAB 190 
function perfcurve.m. The closer the ROC curve approaches the top left-hand corner (100% 191 
sensitivity and 100% specificity) the more accurate is the test. The accuracy of the test is 192 
determined by the area under the curve (AUC). 193 
 194 
2.3 Assessment of diagnostic patterns 195 
In exploratory analyses we looked at the strength of association between gain and 196 
amplitude parameters and the underlying etiology for BVL. As reference subgroups we 197 
9 
selected aminoglycoside-vestibulotoxicity and MD. We pooled gains and amplitude 198 
parameters of both sides into horizontal, anterior and posterior parameters for gain and 199 
amplitude, respectively.  200 
The strength of association of horizontal SCC, anterior SCC and posterior SCC 201 
(independent variates) for each of two etiologies (dependent variate) was examined as 202 
follows: In context of aminoglycoside-related BVL, 1) SNHL was compared to 203 
aminoglycosides, 2) infectious was compared to aminoglycosides and 3) MD was compared 204 
to aminoglycosides. In the context of MD-related BVL, 4) SNHL was compared to MD and 205 
5) infectious was compared to MD. Analyses were performed for gain and cumulative 206 
saccade amplitude separately resulting in 10 different models. The intercept was set to 0. With 207 
these models, we estimated the odds ratios (OR) and 95% confidence-intervals (CI) for each 208 
of the three gain and amplitude parameters for each of the etiology contrasts. Due to the 209 
exploratory nature of this analysis, we refrain from reporting p-values between different 210 
groups of diagnoses. Analyses were performed using Stata 14.0 (StataCorp LP, College 211 
Station, TX). 212 
  213 
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3. RESULTS 214 
One-hundred-nine BVL cases (47 females, 63.8±17.9 years, mean±1SD) were 215 
included. Most frequent causes of BVL were vestibulotoxic drugs (15%), SNHL (10%) and 216 
inner-ear infections (10%) (Table 1 and appendix A).   217 
 218 
3.1 Distribution of affected SCCs 219 
Peripheral-vestibular hypofunction was identified in 466/654 SCCs (71.3%). There 220 
was no significant (p>0.05, Fisher’s exact test) preference of the side affected. While 221 
percentages (left and right side pooled) of horizontal (n=186/218, 85.3%) and posterior 222 
(n=194/218, 89.0%) SCCs with hypofunction were similar (p=0.94), anterior canals were 223 
impaired significantly (p<0.001) less often (n=86/218, 39.5%) (Figures 1 and 2).  224 
 225 
/*Figures 1&2 about here*/ 226 
 227 
We correlated the combination of affected SCCs with the underlying clinical 228 
diagnosis, but restricted this analysis to disorders with a sample size ≥5 to allow for statistical 229 
analysis of these subgroups. Rates were significantly higher for the horizontal and posterior 230 
canals compared to the anterior canals in patients with aminoglycoside-related 231 
vestibulotoxicity, MD and BVL of unknown origin (Table 2 and Figure 2C). From the 66 232 
cases with caloric irrigation available, lateral SCC function (vHIT vs. calorics) matched in 40 233 
cases (60.6%). In half of the discordant cases (13/26), bilateral SCC hypofunction in the vHIT 234 
contrasted with a significant asymmetry ratio in calorics; in six cases calorics were normal 235 
despite bilateral vHIT hypofunction. In the remaining seven cases, unilateral hypofunction 236 
was noted in only one of the two tests.  237 
 238 
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3.2 Analysis of SCC-gains 239 
Reduced gains were found in 438/654 SCCs (67.0%) (Figure 3A). Rates were 240 
significantly (p<0.001) higher for posterior (n=165/218) and horizontal (n=175/218) canals 241 
than for anterior (n=98/218) canals. Median (±1MAD) absolute gain asymmetries were 242 
0.13±0.08 (horizontal canals), 0.13±0.09 (anterior canals), and 0.11±0.08 (posterior canals), 243 
respectively. With no significant lateralization of gains in either plane, further analyses were 244 
done after pooling gains from both sides. While median gains for anterior canals were 245 
significantly higher than those for the horizontal (0.73 vs. 0.54, p<0.001) and posterior (0.73 246 
vs. 0.50, p<0.001) SCCs, there was no significant difference (0.54 vs. 0.50, p=0.480) between 247 
horizontal and posterior canals (Figure 3B). 248 
 249 
/*Figure 3 about here*/ 250 
 251 
In relation to the overall rating of SCC function (based on the assessment by two 252 
experienced neuro-otologists), we calculated the sensitivity and specificity of obtained aVOR 253 
gain values based on currently accepted gain cut-offs for hypofunction (<0.8 for the 254 
horizontal canals; <0.7 for the vertical canals). Both sensitivity (87.6% [95%-CI: 84.6-90.6]) 255 
and specificity (84.0% [78.8-89.6]) were high. 256 
We correlated SCC gains with specific disorders. In accordance with the clinical rating 257 
of canal function, median anterior canal gains were significantly (p<0.001) larger than those 258 
of posterior and horizontal canals (Table 2) for aminoglycoside-related vestibulotoxicity and 259 
BVL of unknown origin. Likewise median gains in Menière-related BVL were significantly 260 
higher for anterior canals compared to posterior canals (p=0.002), but not significantly 261 
(p=0.166) different between anterior and horizontal canals (Figure 4). For BVL related to 262 
CANVAS, SNHL and infections, no significant gain differences between anterior, posterior 263 
and lateral canals were found.   264 
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 265 
/*Figure 4 about here*/ 266 
 267 
3.3 Analysis of compensatory saccades 268 
Cumulative saccade amplitudes were rated as abnormally high in 432/654 canals 269 
(66.1%). Percentages were significantly (p<0.001) higher for horizontal (n=181/218, 83.0%) 270 
and posterior (n=184/218, 84.4%) canals than for anterior canals (n=67/218, 30.7%). In all 271 
subgroups (Table 2) correction saccades were identified significantly (p<0.05) more often for 272 
horizontal than for anterior SCCs. When comparing the anterior and posterior SCCs, 273 
correction saccades were more common in posterior canals only for aminoglycoside-related 274 
vestibulotoxicity, Menière-related BVL and BVL of unknown origin. 275 
We did not observe significant lateralization of saccade amplitudes (Figure 3C). 276 
Pooled amplitudes (Figure 3D) for horizontal canals were significantly higher than those for 277 
posterior (2.46 vs. 1.48°/trial, p=0.001) and anterior (2.46 vs. 0.28°/trial, p<0.001) canals. 278 
Likewise amplitudes for posterior canals were significantly larger than those for anterior 279 
canals (2.46 vs. 0.29°/trial, p<0.001). Median amplitudes (Table 2) of both horizontal and 280 
posterior canals were significantly (p<0.01) larger than those of anterior canals for 281 
aminoglycoside-related vestibulotoxicity, BVL of unknown origin and MD (Figure 4). For 282 
CANVAS, SNHL and inner-ear infections, median saccade amplitudes of horizontal SCCs 283 
were also significantly larger than those of anterior canals (p<0.05), while no significant 284 
difference was found when comparing anterior and posterior canals.  285 
With both gain reduction and correction saccades emerging from SCC hypofunction, 286 
we predicted a substantial inverse correlation between these two parameters. When plotting 287 
gains against saccade amplitudes (Figure 3E), we indeed noted a significant (p<0.001) inverse 288 
relationship, which could be fitted significantly (p=0.019) better with an exponential-decay 289 
function (R2=0.43) than with a linear function (R2=0.38). 290 
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While the largest fraction of hypofunctional SCCs (n=466) had both reduced gains and 291 
significant correction saccades (n=375, 80.5%, based on visual inspection by experienced 292 
neuro-otologists), we found SCCs with hypofunction but absent saccades (n=35, 7.5%) and 293 
SCCs with significant correction saccades but normal gain (n=56, 12.0%). Cumulative 294 
saccade amplitudes in SCCs rated hypofunctional were significantly (p<0.001) smaller in 295 
those SCCs with normal gain than in those with reduced gain (Figure 3F). Likewise gain 296 
values in those SCCs with overall function rated as normal were significantly larger than in 297 
those SCCs with significant correction saccades but normal gain (0.90±0.14 vs. 0.82±0.07, 298 
p=0.027, Kruskal-Wallis ANOVA).     299 
In order to determine the optimal cut-off value for abnormally increased cumulative 300 
saccade amplitudes based on the reviewers’ ratings and the saccade amplitudes (see methods 301 
section for details), a ROC curve for cumulative saccade amplitudes was calculated. With an 302 
area-under-the-curve (AUC) value of 0.94, an optimal cut-off value for cumulative saccade 303 
amplitudes (sensitivity=86.5% [95%-CI=83.4-89.6]; specificity=92.6% [88.8-96.3]) of 304 
0.73°/trial (Figure 5A) was obtained. This cut-off value allowed a reliable distinction between 305 
canals rated as having normal (left column) or reduced (right column) function for cumulative 306 
saccade amplitudes (Fig. 5B). 307 
 308 
/*Figure 5 about here*/ 309 
 310 
Comparing the sensitivity and specificity of aVOR gains (with pre-specified cut-off 311 
values of 0.8 for horizontal SCCs and 0.7 for vertical SCCs) and cumulative saccade 312 
amplitudes (using the cut-off value of 0.73°/trial as determined), no significant differences in 313 
the sensitivity could be observed (OR=0.91 [0.62-1.33]; gains vs. cumulative saccade 314 
amplitudes). For specificity, however, risk for a false positive diagnosis was significantly 315 
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higher when considering gain values than for cumulative saccade amplitudes (OR=2.36 [1.21-316 
4.61]). 317 
In a next step we asked whether an assessment based on both parameters would further 318 
improve sensitivity and specificity. We therefore combined the ratings based on aVOR gains 319 
and on cumulative saccade amplitudes in such a way that a given SCC was considered 320 
hypofunctional if either both or only one of the two ratings yielded an abnormal value (i.e., 321 
gain below cut-off, cumulative saccade amplitude above cut-off). Sensitivity derived from 322 
this combined assessment (96.8% [95.2-98.4]) was significantly higher than sensitivity solely 323 
assessed by aVOR gain (OR=4.27 [2.39-7.66]) or cumulative saccade amplitudes (OR=4.70 324 
[2.63-8.39]). Specificity obtained by pooling both assessments (80.3% [74.6-86.0]) was not 325 
worse than aVOR-gain based specificity (OR=0.77 [0.46-1.32]). However, compared to 326 
sensitivity derived from cumulative saccade amplitudes, specificity in the pooled assessment 327 
was significantly lower (OR=0.33 [0.17-0.63]). 328 
  329 
3.4 Multivariate logistic regression analysis  330 
In comparison to cases with aminoglycoside-related BVL, the gain (OR=0.05 [95%-331 
CI=0.00-0.95]) and saccade amplitude (OR=2.62 [0.98-7.00]) of anterior SCCs in cases with 332 
SNHL made a distinction, with SNHL being very unlikely in case of normal SCC-gain and 333 
small cumulative saccade amplitudes. For aminoglycoside-related BVL vs. BVL linked to 334 
inner-ear infection, again the gain (OR=0.20 [0.02-1.69]) and the saccade amplitude 335 
(OR=2.91 [1.09-7.75]) of the anterior SCC contributed the most in distinguishing these 336 
etiologies, favoring aminoglycoside-vestibulotoxicity over inner-ear infection for normal 337 
anterior gains and saccade amplitudes. For the other subgroups, ORs for gain and saccades 338 
did not help in separating the different disease entities as 95%-CI were very broad including 339 
1.0 (appendix B).   340 
15 
4. DISCUSSION 341 
We found striking differences in the pattern of SCC hypofunction in patients with 342 
BVL. While anterior SCC function was relatively spared in aminoglycoside-vestibulotoxicity, 343 
MD and BVL of unknown origin, SCC hypofunction was evenly distributed among all canals 344 
in BVL related to SNHL, inner-ear infections and CANVAS. Gain-reductions (reflecting 345 
aVOR-impairment) and emerging compensatory saccades (triggered by retinal slip) were 346 
highly correlated, strongly supporting the assessment of both parameters to identify 347 
peripheral-vestibular hypofunction. Noteworthy, both approaches have their advantages and 348 
disadvantages, which is reflected in the observation that 12% of SCCs had increased 349 
cumulative saccade amplitudes but still normal gains. Noteworthy, the use of cumulative 350 
saccade amplitudes as a parameter of peripheral-vestibular hypofunction has been so far 351 
limited by lack of established cut-off values. Based on ROC curves we found an optimal cut-352 
off value of 0.73°/trial for cumulative saccade amplitudes in our patient cohort with bilateral 353 
vestibular loss. For this cut-off we achieved high sensitivity (86.5%) and specificity (92.6%). 354 
Noteworthy, this value matches very well the observed cut-off of 0.78°/trial in a small case-355 
control series with patients with unilateral and bilateral vestibulopathy published very 356 
recently (MacDougall et al. , 2016).  357 
The significantly higher specificity when considering cumulative saccade amplitudes 358 
instead of gain values (OR=2.36) further underlines the advantages of taking cumulative 359 
saccades into account in the overall assessment. Thereby false positive ratings by erroneously 360 
low gain values (e.g. due to slippage of the vHIT goggles) may be avoided. As a result, 361 
combining both aVOR-gain based and saccade-based ratings significantly increased the 362 
sensitivity of the vHIT (92.4%) compared to the use of a single parameter only, while 363 
specificity remained high (being not worse than for ratings based on aVOR gains solely).  364 
 365 
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4.1 Disease-specific sparing of the anterior SCCs 366 
Considering the disease-specific sparing of the anterior SCCs, vHIT may allow the 367 
distinction between BVL related to aminoglycosides or MD and BVL associated with inner-368 
ear infections or SNHL. This is underlined by logistic regression analysis: both gains and 369 
saccade amplitudes of anterior SCCs helped in distinguishing between aminoglycoside-370 
related BVL and BVL secondary to SNHL or inner-ear infections. Anterior SCC-sparing was 371 
noted also in BVL of unknown origin. It is reasonable to assume that aminoglycoside-372 
vestibulotoxicity and MD may be underdiagnosed and they potentially make up a significant 373 
fraction of all BVL cases of unknown origin.  374 
With regards to cumulative saccade amplitudes, disease-specific sparing of anterior 375 
SCC function was found only when comparing anterior and posterior SCC function, whereas 376 
amplitudes of horizontal SCCs were significantly higher in all subgroups compared to those 377 
of the anterior SCCs. These differences can be explained by the way the head-impulse-test is 378 
performed: due to biomechanical reasons, horizontal head impulses are applied with 379 
somewhat larger amplitudes than vertical head impulses. Therefore, resulting correction 380 
saccades in case of SCC hypofunction will be larger for the horizontal than for the vertical 381 
SCCs, while the vertical canals are always tested in pairs (LARP and RALP planes), allowing 382 
direct comparison between anterior and posterior SCCs. For the analysis of cumulative 383 
saccade amplitudes, sparing of anterior SCC function is a disease-specific marker only when 384 
compared to posterior SCC function. 385 
Previously, Agrawal and colleagues reported oVEMPs to be the most sensitive test to 386 
distinguish between aminoglycoside-related vestibulotoxicity and bilateral MD with the latter 387 
disease showing relative sparing of oVEMP-function compared to the first one (Agrawal et al. 388 
, 2013). Since SCC function was only assessed using calorics by Agrawal and colleagues and 389 
since we did not incorporate oVEMP-measurements here, this leaves the question open, to 390 
which extent differences in anterior/horizontal SCC correlate to otolith-function. 391 
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Anterior SCC-sparing may originate from different causes, including distinct 392 
vulnerability of ampullary hair cells to vestibulotoxic substances or increased endolymphatic 393 
pressure and superior recovery after damage.  394 
Aminoglycosides are hydrophilic drugs with low protein-binding and a molecular 395 
weight between 450 and 600g/mol. They accumulate in the endolymph and perilymph (Tran 396 
Ba Huy et al. , 1983), readily penetrate the hair cells and accumulate with a long second half 397 
life (gentamicin about 30 days) (Tran Ba Huy et al. , 1986). After systemic aminoglycoside 398 
administration dose dependent toxicity in the vestibular hair cells - especially in the 399 
epithelium of the cristae ampullaris (Lindeman, 1969, Nakagawa et al. , 1998, Tsuji et al. , 400 
2000) was observed. Pathophysiologically, aminoglycosides are believed not to be toxic 401 
unless chelated to a metal ion and subsequent generation of reactive oxygen species, cell 402 
apoptosis and necrosis (Hoch et al. , 1998). A large proportion of hair cells were affected in 403 
the ampulla and in the utricule (Aran et al. , 1982). Most results were derived from animal 404 
studies (e.g. guinea pigs) where anatomic differences to humans may account for 405 
discrepancies in susceptibility to ototoxicity. However, to our knowledge, there is no 406 
confirmation of preferential damage of the posterior and horizontal canals in animal models 407 
after systemic application of aminoglycosides. Three weeks after intratympanic application of 408 
gentamicin in chinchilla, rates of type 1 hair-cell density reduction were similar in the 409 
ampullae of horizontal and vertical canals (range=63-73%) (Lyford-Pike et al. , 2007), not 410 
supporting the hypothesis of selective damage of type 1 hair cells in posterior and horizontal 411 
SCCs. 412 
Theoretically, accumulation of the drug may be influenced by the pull of gravity. 413 
Noteworthy, basal outer cochlear hair cells were reported to be more vulnerable than apical 414 
outer hair cells (Tan 2001), which could be related to basal accumulation of aminoglycosides. 415 
As the posterior and horizontal canals are located below the anterior canal when in a 416 
horizontal body position (as typically experienced in severely-ill patients treated with 417 
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aminoglycosides), accumulation of aminoglycosides at the lowest point would result in higher 418 
concentrations in the posterior and horizontal SCCs. A prerequisite for this hypothesis related 419 
to gravity is that the molecular density of aminoglycosides is higher than that of endolymph. 420 
A complexation and chelation with metal ions could also lead to decreased solubility and 421 
subsidence within the lymph fluid along gravitation.  422 
Histopathological studies reporting on the relative frequency of hydrops of the otolith 423 
organs and individual SCCs are rare. In a study on temporal-bone specimens of patients with 424 
MD, hydrops was reported less frequently for the SCCs (n=10/22) compared to the otolith 425 
organs (n=19/22) (Okuno et al. , 1987). Differences in the rate of affected posterior (n=8), 426 
anterior (n=6) and horizontal (n=6) canals were non-significant, though the small sample 427 size gave the test low power. How SCC hypofunction secondary to endolymphatic hydrops 428 
in MD therefore occurs at distinct rates for the individual SCCs remains unclear. Imaging of 429 
structural changes of the vestibular organs using MRI is a recent diagnostic approach in 430 
patients with suspected MD. Reduced or absent perilymphatic enhancement after 431 
intratympanic gadolinium application was used as an indirect sign of endolymphatic hydrops, 432 
reporting larger fractions of affected canals for anterior SCCs than for horizontal SCCs (62% 433 
vs. 46%) (Fiorino et al. , 2011). This finding is opposite to the relative sparing of anterior 434 
SCCs described here. However, whether structural changes on the level of individual SCCs 435 
correlate with functional SCCs deficits has not been evaluated. 436 
While in the evolution of the vertebrate labyrinth (see (Carey et al. , 2006)) the 437 
original pair of vertical SCCs (as in the lamprey (Lowenstein et al. , 1968)) was 438 
complemented later by a third, horizontal SCC that develops after the vertical canals (Sher, 439 
1971) and grows at a slower rate (Jeffery et al. , 2004), this does not explain relative sparing 440 
of anterior canals in aminoglycoside-related vestibulotoxicity and MD. Theoretically, anterior 441 
SCC sparing could be a measurement bias. This, however, seems unlikely for several reasons. 442 
First, sparing was restricted to certain disorders. Second, the vertical SCCs are always tested 443 
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in pairs according to their planes of stimulation and head impulses of similar velocities were 444 
applied for all vertical SCCs. Third, anecdotally, patients reported oscillopsia for upward 445 
head-movements only, but not for downward head movements, matching their vHIT-pattern 446 
of spared anterior SCCs.  447 
 448 
4.2 Limitations 449 
There is no other established test to assess SCC-function in such detail as the vHIT 450 
does, limiting the validation process of vHIT results. Both the established gold standard 451 
(caloric irrigation) and rotatory chair testing are limited to the horizontal SCCs and magnetic 452 
search coils (see e.g. (Weber et al. , 2009a)) are available only in few specialized vestibulo-453 
ocular motor laboratories. Caloric irrigation was available only in 61% of patients studied. 454 
The largest fraction of discordant ratings (50%) was related to a significant asymmetry ratio 455 
in calorics while the vHIT indicated bilateral hypofunction. Noteworthy, a significant canal 456 
paresis factor in calorics does not necessarily implicate normal SCC-function on the side with 457 
the larger response; it only indicates different levels of SCC-function on both sides. 458 
Importantly, unilateral vestibular hypofunction is often accompanied by compensatory down 459 
regulation of the aVOR gain and catch-up saccades on the healthy side (Weber et al. , 2008), 460 
which may mimic bilateral (asymmetric) vestibular hypofunction. Such misclassification by 461 
our reviewers cannot be fully excluded, however, considering the low range of gain 462 
asymmetries in pairs of SCCs rated as bilaterally abnormal (0.11±0.10, median±1MAD), this 463 
seems unlikely.  464 
In order to determine an optimal cut-off value for cumulative saccade amplitudes in 465 
affected semicircular canals, the qualitative ratings of two expert neuro-otologists were 466 
considered as reference standard. Obviously, this bears the risk of inter-observer variability, 467 
however, ratings were independently obtained and discrepancies were settled by discussion. 468 
Whether the cut-off value obtained (0.73°/trial) is valid also for other peripheral-vestibular 469 
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disorders (e.g. acute unilateral vestibular neuropathy), however, is subject to future (ideally 470 
prospective) studies. 471 
With the underlying cause of BVL remaining unclear in 47 cases, both labyrinthine 472 
and retro-labyrinthine disorders may be considered. Brain imaging (MRI in 38 cases; CT in 3 473 
cases) was available in 41 cases, demonstrating definite unilateral retro-labyrinthine 474 
pathologies in only 2 cases (both vestibular schwannoma) while no pathologies along the 475 
vestibular nerve were described in the remaining 39 cases. Overall, imaging does not provide 476 
a convincing explanation for the bilateral SCC hypofunction in any of the unclear cases that 477 
received imaging (87.2%). Furthermore, with presumed retro-labyrinthine pathology, rather a 478 
pattern of posterior canal sparing (in case of superior branch vestibular neuropathy), anterior 479 
and horizontal canal sparing (in case of inferior branch vestibular neuropathy) or involvement 480 
of all SCCs (e.g., in case of vestibular schwannoma) would be predicted based on the 481 
innervation and vascularization of the vestibular organ. Regarding the small fraction of cases 482 
with confirmed retro-labyrinthine disorders (3 cases, mostly vestibular schwannoma), no 483 
anterior canal sparing was observed in these cases.  484 
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5. CONCLUSIONS 485 
Peripheral-vestibular mapping with vHIT including all six SCCs may be considered in 486 
patients with suspected BVL for differentiating between distinct disease etiologies. Sparing of 487 
anterior SCCs may point to aminoglycoside-related vestibulotoxicity or MD. With 12% of 488 
cases showing correction saccades but normal gain values, we propose to include saccade 489 
amplitudes into the overall rating of canal function to increase sensitivity. We could not 490 
identify any morphological, functional or developmental differences between the anterior and 491 
posterior SCCs that may provide a convincing explanation for disease-specific anterior-SCC 492 
sparing. Mechanistic models investigating effects of aminoglycoside- or MD-related toxicity 493 
in the more caudally located SCCs (i.e., the lateral and posterior canals) should clarify 494 
preferential damage location in further studies.  495 
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FIGURE LEGENDS 610 
Figure 1: 611 
Video-head-impulses from a single patient demonstrating bilateral vestibular deficits 612 
related to aminoglycoside-induced vestibulotoxicity. Eye velocity traces (in black) and head 613 
velocity traces (in grey) are plotted against time. Peripheral-vestibular hypofunction was 614 
diagnosed here for both horizontal and both posterior SCCs based on reduced gains (<0.8 for 615 
the horizontal SCCs; <0.7 for the vertical SCCs; as also shown in the center hexplot) and 616 
increased cumulative saccade amplitudes. In this patient the anterior SCCs were bilaterally 617 
spared. 618 
 619 
Figure 2: 620 
Summary figures on the distribution of peripheral-vestibular hypofunction in our 109 621 
patients, illustrating both the fractions with hypofunction for the different SCCs as a hexplot 622 
(panel A) and the relative frequency of specific combinations of SCC hypofunction (panel B). 623 
*Diverse combinations included one case each with SCC hypofunction bilateral anterior 624 
unilateral horizontal, bilateral anterior unilateral posterior, bilateral horizontal unilateral 625 
anterior and horizontal, bilateral anterior and horizontal unilateral posterior, bilateral posterior 626 
unilateral anterior and horizontal, bilateral anterior, unilateral horizontal & anterior (left side) 627 
and unilateral posterior (right side). Panel C: Comparison of the relative frequency of 628 
peripheral-vestibular SCC hypofunction in different planes (based on the reviewers ratings) 629 
and for distinct underlying disorders (note that only subgroups with an n≥5 were considered). 630 
This value is provided as a ratio calculated by dividing the fraction of anterior SCCs with 631 
hypofunction by the pooled and averaged fraction of horizontal and posterior SCCs with 632 
hypofunction. Here this ratio is plotted against the number of patients with this diagnosis, 633 
showing significant anterior SCC-sparing in aminoglycoside-related BVL, MD and BVL of 634 
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unknown origin (ratio=0.2-0.3), but not in the other subgroups (ratio=0.8-0.9). For infection-635 
related BVL and CANVAS the ratio was identical (0.8), therefore these subgroups were 636 
plotted above each other.  637 
Abbreviations: SNHL= sensorineural hearing-loss; LA=left anterior SCC; LH=left horizontal 638 
SCC; LP=left posterior SCC; RA=right anterior SCC; RH=right horizontal SCC; RP=right 639 
posterior SCC. 640 
 641 
Figure 3: 642 
Comparison of gain values (panels A and B) and cumulative saccade amplitudes 643 
(panels C and D) in the BVL patients. Panel A: A hexplot is used to illustrate the distribution 644 
of median (±1 MAD) gain values for all six SCCs separately. Since statistical analysis 645 
(Tukey-Kramer corrected for multiple comparisons) did not find effects of laterality, gain 646 
values from corresponding SCCs on the left and right side were pooled, as shown in panel B 647 
including all 654 canals. Panel C:  Hexplot illustrating the cumulative saccade amplitudes for 648 
all six SCCs separately in all BVL patients. Again, values from corresponding left and right 649 
SCCs were pooled for further analysis, as shown for all 654 SCCs in panel D. Panel E: Gain 650 
values are plotted against the cumulative saccade amplitudes for all canals and patients tested, 651 
demonstrating a significant inverse correlation for both fits. In comparison, the fit of the 652 
exponential decay function is significantly better than the linear fit (p=0.019, F-test). Panel F: 653 
comparison of cumulative saccade amplitudes for trials rated as having peripheral-vestibular 654 
hypofunction but normal (left column) or reduced (right column) gain. In the box and whisker 655 
plots used for panels B, D, and F the box has lines at the lower quartile, the median and the 656 
upper quartile values. Notches represent the 95% confidence interval around the median. 657 
Whiskers extend from each end of the box, including data points within approximately 2.7 658 
standard deviations of the median. Outliers („+“ signs) are data with values beyond the ends 659 
of the whiskers. * indicates statistically significant differences (p<0.05) based on non-660 
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parametric Kruskal-Wallis ANOVA and multiple comparisons with Tukey-Kramer 661 
correction, ns refers to statistically non-significant differences. For explanation of other 662 
abbreviations see legend of Figure 2. 663 
 664 
Figure 4: 665 
Hexplots illustrating the median gain values (±1MAD) and the cumulative saccade 666 
amplitude for all six SCCs separately in the most frequent diseases linked to BVL observed in 667 
our study population. While the anterior canals yielded higher gains and lower saccade 668 
amplitudes for aminoglycoside-related BVL (panel A), BVL of unknown origin (panel B) and 669 
BVL related to Menière’s disease (panel C), gain values for all six canals were reduced in a 670 
similar fashion for CANVAS (panel D), sensorineural hearing-loss (SNHL, panel E) and BVL 671 
linked to inner-ear infections (panel F). The same picture was found for the distribution of 672 
cumulative saccade amplitudes (panels G-L). 673  674 
Figure 5: 675 
Panel A: Receiver operating characteristic (ROC) curve analysis for an optimal cut-676 
point of cumulative saccade amplitudes to detect a pathological video-head-impulse test. The 677 
closer the ROC curve approaches the top left-hand corner (100% sensitivity and 100% 678 
specificity) the more accurate is the test. The accuracy of the test is determined by the area 679 
under the curve (AUC), reaching 0.94 for cumulative saccade amplitudes here. Noteworthy, a 680 
perfect test has an AUC=1, whereas a worthless test such as the hypothetical reference 681 
diagonal line has an AUC=0.5. The stars indicate the optimal cut-off point for cumulative 682 
saccade amplitudes.  In panel B cumulative saccade amplitudes for canals judged as normal 683 
are compared with those rated as abnormal with the dashed black line indicating the optimal 684 
cut-off point (cumulative saccade amplitude=0.73°/trial). The grey dots refer to individual 685 
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canals. In the box and whisker plots used for panel B the box has lines at the lower quartile, 686 
the median and the upper quartile values. Whiskers correspond to approximately ±2.7σ of the 687 
median. Outliers („+“ signs) are data with values beyond the ends of the whiskers.  688 
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TABLES 689 
Table 1: epidemiological findings of the 109 patients with BVL 
  SCCs with hypofunction (%) 
Disease Cases (%) LE hor RE hor LE ant RE ant LE post RE post 
Unknown 47 (43.1) 39 (83.0) 39 (83.0) 12 (25.5) 11 (23.4) 41 (87.2) 44 (93.6) 
Vestibulotox. drugs ‡ 16 (14.7) 16 (100) 14 (87.5) 5 (31.3) 4 (25.0) 16 (100) 16 (100) 
Bilateral SNHL 11 (10.1) 10 (90.1) 10 (90.1) 9 (81.8) 7 (63.6) 10 (90.1) 10 (90.1) 
Infectious 11 (10.1) 11 (100) 9 (81.8) 8 (72.7) 8 (72.7) 9 (81.8) 9 (81.8) 
Menière’s disease 10 (9.2) 6 (60.0) 5 (50.0) 2 (20.0) 1 (10.0) 6 (60.0) 9 (90.0) 
CANVAS 5 (4.6) 5 (100) 5 (100) 4 (80.0) 4 (80.0) 5 (100) 5 (100) 
Autoimmune * 2 (1.8)  2 (100) 2 (100) 2 (100) 1 (50.0) 2 (100) 2 (100) 
Bilat. schwannoma 2 (1.8) 2 (100) 2  (100) 1 (50.0) 2 (100) 1 (50.0) 2 (100) 
Head trauma 2 (1.8) 2  (100) 1 (50.0) 1 (50.0) 1 (50.0) 2 (100) 2 (100) 
Central causes † 1 (0.9)  1 (100) 1 (100) 1 (100) 0 (0.0) 0 (0.0) 1 (100) 
Schwannoma + VN § 1 (0.9) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 
Fabry disease 1 (0.9) 1 (100) 1 (100) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Total 109 (100) 96 (88.1) 90 (82.6) 46 (42.2) 40 (36.7) 93 (85.3) 101 (92.7) 
 690 
Abbreviations: ant=anterior; bilat=bilateral; CANVAS=cerebellar ataxia with neuropathy and 691 
bilateral vestibular areflexia syndrome; hor=horizontal; LE=left; post=posterior; RE=right; 692 
SNHL=sensorineural hearing loss; VN=vestibular neuritis 693 
 694 
* One case of possible Cogan’s syndrome, one case with autoimmune-related disorder 695 
possibly associated with neurosarcoidosis. 696 
† MRI-confirmed cavernoma in the left brachium pontis with possible involvement of the 697 
vestibular nuclei. 698 
‡ This includes the following aminoglycosides: Gentamicin (n=12), Tobramicin (n=2) and 699 
Streptomycin (n=1). In one case the type of aminoglycoside remained unclear.  700 
§ Sequential occurrence of vestibular schwannoma on one side and vestibular neuritis on the 701 
other side (n=1).702 
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Table 2: Subgroup analyses for gain and saccades 
 
 
Reviewers’ ratings of SCC function 
 
 global ratings  
(based on gain and correction saccades) 
ratings based on correction saccades only 
 SCC hypofunction  
(left / right side pooled) 
p-value  
(Fisher’s exact test*) 
significant correction saccades  
(left / right side pooled) 
p-value  
(Fisher’s exact test*) 
Disease hor SCC ant SCC post SCC hor vs. 
ant 
hor vs. 
post 
ant vs. 
post 
hor SCC ant SCC post SCC hor vs. 
ant 
hor vs. 
post 
ant vs. 
post 
Unknown 78/94 23/94 85/94 <0.001 0.197 <0.001 74/94 17/94 79/94 <0.001 0.454 <0.001 
Aminoglycosides 30/32 9/32 32/32 <0.001 0.585 <0.001 30/32 7/32 32/32 <0.001 0.585 <0.001 
SNHL 20/22 16/22 20/22 0.241 1.000 0.241 20/22 13/22 18/22 0.034 0.655 0.185 
Infectious 20/22 16/22 18/22 0.241 0.655 0.721 20/22 13/22 18/22 0.034 0.655 0.185 
Menière 11/20 3/20 15/20 0.019 0.320 <0.001 11/20 3/20 14/20 0.019 0.515 0.001 
CANVAS 10/10 8/10 10/10 0.540 1.000 0.540 10/10 5/10 10/10 0.034 1.000 0.034 
 
Measured gains and cumulative saccade amplitudes 
 
 vHIT gains correction saccades 
 gain value 
(median±1MAD) 
p-value  
(Kruskal-Wallis ANOVA†) 
cumulative saccade amplitude [°/trial] 
(median±1MAD) 
p-value  
(Kruskal-Wallis ANOVA†) 
Disease hor SCC ant SCC post SCC hor vs. 
ant 
hor vs. 
post 
ant vs. 
post 
hor SCC ant SCC post SCC hor vs. 
ant 
hor vs. 
post 
ant vs. 
post 
Unknown 0.58±0.19 0.82±0.16 0.58±0.18 <0.001 0.722 <0.001 2.33±1.14 0.20±0.20 1.58±0.94 <0.001 0.049 <0.001 
Aminoglycosides 0.46±0.17 0.77±0.15 0.41±0.12 <0.001 0.961 <0.001 2.66±1.29 0.38±0.34 1.85±0.78 <0.001 0.350 <0.001 
SNHL 0.47±0.26 0.61±0.23 0.53±0.20 0.500 0.994 0.564 1.60±1.20 0.47±0.40 1.36±0.89 0.004 0.136 0.411 
Infectious 0.36±0.21 0.48±0.15 0.28±0.09 0.302 0.972 0.204 3.41±0.92 1.59±1.19 1.71±1.14 0.004 0.078 0.544 
Menière 0.76±0.17 0.99±0.11 0.61±0.13 0.166 0.248 0.002 1.01±0.77 0.02±0.02 1.16±0.35 <0.001 0.629 0.008 
CANVAS 0.13±0.07 0.31±0.17 0.30±0.13 0.137 0.442 0.772 4.42±0.68 0.58±0.58 2.15±1.08 0.012 0.503 0.195 
 
Abbreviations: ant=anterior; CANVAS=cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome; SNHL=sensorineural 
hearing-loss, hor=horizontal: MAD=median absolute deviation; post=posterior; SCC=semicircular canal; vHIT=video-head-impulse test 
 
* With Bonferroni correction for multiple tests. 
† With Tukey-Kramer correction for multiple tests. 





